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SuStainable HealtH Care SyStemS: tHe role of tHeraPeutiC Value and 
Value baSed PriCing
Hulshof J.A.M.
Simon-Kucher & Partners, Bonn, Germany
It is a common perception that the cost of pharmaceutical care, driven by the price 
of medicines, is a major contributor to increasing public health care expenditure, 
the culprit of unsustainability of health care systems. This presentation shows how 
the net effect of value-based pricing of new, innovative treatments and competi-
tive pricing of older, often generic, products defeats that perception. The growth 
of pharmaceutical expenditure is, in fact, leveling off in most European countries, 
a trend that started even before the economic crisis of 2008. Value based pricing 
is an approach by which the pricing strategy is determined by therapeutic value, 
economic value and cost-effectiveness. Value based pricing requires a substan-
tial body of sophisticated evidence, generated throughout product development. 
Competitive pricing is an approach by which the pricing strategy of older products 
is defined relative to the price of direct competitors in order to maximize market 
share. Competitive pricing occurs in crowded markets with multiple equal or undif-
ferentiated treatment options. In recent years, competitive pricing has brought the 
price of many widely prescribed drugs significantly down. These two approaches 
to strategic pricing take place against the backdrop of tightening public financing 
rules that aim at ensuring financial sustainability of publicly financed health care 
systems. Consequence thereof is a two-tiered market access decision-making rou-
tine: for high-value/high-priced innovative treatments centralized decision-making 
based on value assessment with evidence, restricting them to a tightly characterized 
severely ill patient sub-population with low volume and/or a sales ceiling; versus 
local decision-making based on lowest (net) price for high-volume multisource 
products or equivalent single-source products, leading to significantly lower (net) 
prices than the originator at time of launch. Sustainable pharmaceutical care with 
openness towards innovation is therefore within reach.
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eConomiC eValuation in Portugal – eStabliSHment of tHe national 
HealtH teCHnology aSSeSSment SyStem (SinatS)
Cortegaça P., Silva F., Viana D., Ramos R., Martins  J.
INFARMED, I.P., Lisbon, Portugal
Economics is a social science that has a focus on allocating limited resources effi-
ciently. In health care is essential to invest properly, assuring access to health tech-
nologies with the best cost-effective profile, ensuring the sustainability of National 
Health Systems. In Portugal, the INFARMED – National Authority of Medicines and 
Health Products I.P., has been making economic evaluations of medicines for 15 
years, and is currently developing the National Health Technology Assessment 
System – SiNATS, of the utmost importance to the National Health System. 
Nowadays the assessment of the technologies (relative effectiveness assessment 
and cost-effectiveness) is focused on medicines, within the reimbursement process 
and the preliminary assessment to its acquisition by the National Health System’s 
Hospitals. Consequently, it is always done before the reimbursement decision, as 
a supporting tool to the decision itself. The purpose of this model is to guarantee 
a global system, and at the same time, extending it to new technologies besides 
medicines, e.g. medical devices. In these cases, the cost-effectiveness evaluation will 
be done through the whole life-cycle of that technology, affecting its price and use 
considering its real performance; instead of only its market entry. The INFARMED, 
by developing SiNATS, intends to contribute to minimize expenditures in health and 
the citizens’ life quality, in order to assure the National Health System’s sustain-
ability and efficient usage of public resources in health. Moreover, this system also 
aims to observe the technologies’ effectiveness and its usage, with the purpose of 
reducing wastes as well as to promote and award innovation and equal access to 
health technologies. This research intends to verify the applicability of the univer-
sal key principles of Health Technology Assessment Systems in SiNATS, in order 
to guarantee that the model achieves its proposing objectives. The study will be 
focused on the structure of system.
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market aCCeSS and reimburSement oPtionS for orPHan durg 
HoSPital only mediCineS in euroPe – one Size fitS all?
Vosgerau S.1, Paulus G.1, Plantoer S.2
1IMS Health, Munich, Germany, 2IMS HEALTH GmbH & Co. OHG, Munich, Germany
Orphan drugs are medicines used to the treat life-threatening or chronic diseases 
affecting very rare diseases. From April 2000 to October 2010, 720 drugs received 
orphan drug designation from the European Medicines Agency (EMA). Hereof, 63 
were granted marketing a marketing authorization. Since then - with an annual 
orphan drug sales volume of more than $6 billion - there has been a steady increase 
in applications for orphan designation with the Committee for Orphan Medicinal 
Products (COMP), averaging ten positive recommendations per month. Although 
central approval of orphan drugs covers 30 European countries, it does not neces-
sarily provide for national availability as each national authority has to agree to 
market access and reimbursement. Further, the hospital sector is known for its 
high diversity in terms of national access mechanisms and degree of centralization, 
exemplified by the Nordic Countries: In Denmark and Norway a highly centralized 
hospital sector prevails with one main hospital procurement agency (AMGROS in 
Denmark and LIS in Norway), while in Sweden and Finland several county councils 
are authorized to make decisions independently from each other. The objective of 
the present study is to identify and evaluate possible short cut routes to market 
access and reimbursement for orphan drug hospital only medicines (OD-HOM) in EU 
and further investigate country specific requirements for identified short cut routes 
to market access and reimbursement for OD HOM in EU as strategic options. A litera-
ture review and further desk research was performed. The following countries are 
included in the analysis: Nordic Countries, Germany, France, The Netherlands and 
Spain. The results of the ongoing OD-HOM research will be displayed as a summary 
challenges to overcome regarding the overall ethics system. Applying same ethics 
regulations or guidelines from interventional studies may not be the most adequate 
choice for observational studies.
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State of tHe art reSearCH in auStria: dexHelPP - deCiSion SuPPort 
for HealtH PoliCy and Planning: metHodS, modelS and teCHnologieS 
baSed on exiSting HealtH Care data
Zauner G.1, Popper N.1, Breitenecker F.2
1dwh GmbH, Vienna, Austria, 2Vienna University of Technology, Vienna, Austria
The Austrian health care system incurs costs of 30 billion/year, the bulk of the costs 
(77%) are publicly financed. Health policy and decision planning based on research 
evidence helps to tackle increasing costs. The urgent need for the evaluation of 
new health technologies, services, infrastructure, as well as for the development 
of improved technologies for the analysis, planning and control of health systems 
is met by DEXHELPP. Methods: Today, decision support in health care is usually 
based on evidence from studies of limited size, but not yet on the analysis of 
large volumes of routinely collected health care data. DEXHELPP is dedicated to 
filling the gap by combining academic excellence by research partners with profes-
sional implementation including knowledge of commercial partner institutions. 
By doing so special methods for statistical analysis, simulation and visualisation 
will be implemented as well as new methods for documentation and provid-
ing of k-anonymity for used individual data. For this task, existing cooperation 
schemes provide a firm substantial and conceptual knowledge base. All relevant 
fundamental technological competencies from academic and applied research 
are provided by the consortium, coming from universities, competence centres, 
and R&D SMEs. Results: Developed methods will help in (1) analysing the status 
quo, (2) making reliable prognoses, and (3) evaluating the consequences of inter-
ventions. A scientific research server with routine data in order to test developed 
methods will be run. The project covers all relevant areas within this complex pro-
cess, from data management via analysis and modelling through to user friendly 
presentation of results and quality assurance. Some of the most important actual 
decision-makers in Austria complete the consortium with application-oriented 
expertise. ConClusions: DEXHELPP focusses on the development on high inno-
vative technological methods. Future focus will lay on building up a network 
with more stakeholders to integrate those methods in national and international 
processes.
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ProPoSed framework for Patient and PubliC inVolVement in tHe Hta 
ProCeSS in ireland
Walsh C.
Trinity College Dublin, Montenotte, Ireland
The rationale for patient and public involvement (PPI) in the Health Technology 
Assessment (HTA) process has been widely documented. Engagement of patients or 
public in the process facilitates a broadening of scope and delineates a role for the 
patient as an ‘expert witness’ who has unique insight to living with an illness and 
the potential benefits/disadvantages (including side effects) that medical technol-
ogy may offer. Our objective was to explore the concept of practical and meaningful 
public participation in the HTA process and present a research protocol to propose 
a PPI framework applicable to the Irish context. A qualitative systematic literature 
review and concept analysis was used to identify key attributes relating to patient 
and public involvement. It is proposed that this knowledge will be supplemented 
through semi-structured interviews of key informants and a review of a purposive 
sample of HTA agency websites. Researchers, decision makers and policy makers 
will contribute to development and refinement a framework through a process of 
deliberation. Capturing the diverging perceptions of key informants will lead to the 
enhancement of the proposed framework. The role of the publics will be clarified, 
various levels and methods of PPI further defined. This research will explore the 
concept of PPI and suggest a study protocol for the development of a framework for 
PPI in the context of the Irish HTA process.
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Patient aCCeSS to life-SaVing mediCation; PreVenting StoCk-outS 
due to Parallel trade
Ratcliffe M.1, Mbanya Z.2, Gielen V.1, Sparrowhawk K.1
1PHMR Associates, London, UK, 2PHMR Associates, Newcastle Upon Tyne, UK
Manufacturers and suppliers of potentially life-saving drugs must ensure adequate 
supplies of in-date drug formulations for all markets across Europe. Failure to do 
so risks patient lives, but stock-outs have occurred even when a manufacturer has 
“over-supplied” a market with many times the amount of drug expected to meet 
local demand. These stock-outs have occurred as a result of parallel trade. In these 
cases, as little as a 10% variance on pack cost is enough to trigger parallel trade, 
which can result from price variations at launch across the EU and currency fluc-
tuations following launch. These situations form a useful series of case studies to 
determine supply chain issues leading to stock-outs. Based on this case study analy-
sis, a model is being developed to estimate the degree of exposure to risk of parallel 
trade and its associated potential cost to the manufacturer/supplier, and to patient 
access. The model identifies and quantifies trade flow patterns and key elements. 
Consequently, supply planning is possible based on essential metrics identified in 
the trade flow patterns. An allocation scheme to meet local needs is the key output 
of the model. The allocation scheme is applied to limit stock to the country to be 
in line with demand, plus a smaller variance (depending on local conditions) for 
that market compared to that previously applied. The model is intended for use in 
key EU markets (France, Germany, Italy,  The Netherlands, Spain, Italy, UK) as well 
as countries in Central and Eastern Europe. The model should help to optimise 
supply chain planning and operations, thereby minimising the risk of stock-outs. 
Consequently, all patients requiring specific, potentially life-saving drugs should 
have access to these treatments.
